Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
NYSE MKT:NBY
Holding NBY?
Track your performance easily
NBY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $10.15
Previous Close$0.57
Volume64.78K
Average Volume (3M)2.85M
Market Cap
$2.81M
Enterprise Value$3.29M
Total Cash (Recent Filing)$776.00K
Total Debt (Recent Filing)$1.26M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Mar 27, 2025EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-35.47
Shares Outstanding4,885,693
10 Day Avg. Volume78,808
30 Day Avg. Volume2,846,013
Standard Deviation0.23
R-Squared0.03
Alpha-0.09
Financial Highlights & Ratios
Price to Book (P/B)2.61
Price to Sales (P/S)0.25
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.29
Enterprise Value/Gross Profit0.42
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$0.85Price Target Upside49.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
NovaBay Pharma News
PremiumCompany Announcements
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes
Bulls Say, Bears Say
Bulls Say
Asset SaleThe sale of DERMAdoctor should reduce its cash burn and allows it to focus on pursuing newer and stronger growth opportunities that are better aligned with its core eyecare business.
Financial PositionNovaBay accepted an increased offer of $11.5 million for its Avenova assets, which may benefit the company's financial position.
Market ExpansionNovaBay is making good progress to market its Avenova product to the 41 million Americans who suffer from blepharitis and related eye symptoms.
Bears Say
Business OperationsFollowing the approval and sale of the Avenova assets, the company is expected to liquidate and wind down operations.
Financial PerformanceNovaBay reported Q3 revenue lower than both analyst estimates and consensus.
Guidance And Future OutlookThe company did not provide 2024 guidance, which creates uncertainty for investors.
---
Ownership Overview
10.17%
Insiders
0.14% Mutual Funds
1.48% Other Institutional Investors
88.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NBY FAQ
What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $0.36 and its highest was $10.15 in the past 12 months.
What is Novabay Pharmaceuticals’s market cap?
Currently, no data Available
When is Novabay Pharmaceuticals’s upcoming earnings report date?
Novabay Pharmaceuticals’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Novabay Pharmaceuticals’s earnings last quarter?
Novabay Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.305 by -$0.295.
Is Novabay Pharmaceuticals overvalued?
According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Undervalued.
Does Novabay Pharmaceuticals pay dividends?
Novabay Pharmaceuticals does not currently pay dividends.
What is Novabay Pharmaceuticals’s EPS estimate?
Novabay Pharmaceuticals’s EPS estimate is -$0.24.
How many shares outstanding does Novabay Pharmaceuticals have?
Novabay Pharmaceuticals has 4,885,693 shares outstanding.
What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
Novabay Pharmaceuticals reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.305. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
Currently, no hedge funds are holding shares in NBY
---
NovaBay Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.85 (49.78% Upside)
$0.85 (49.78% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.78%
12-Months-Change
Fundamentals
Return on Equity
-246.52%
Trailing 12-Months
Asset Growth
-69.83%
Trailing 12-Months
Company Description
Novabay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
---
NBY Earnings Call
Q2 2024
0:00 / 0:00
---
NBY Stock 12 Month Forecast
Average Price Target
$0.85
▲(49.78% Upside)
Technical Analysis
Best Analysts Covering NBY
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-62.39%
reiterated a buy rating last month
Copying Edward Woo's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -62.39% per trade.
---